Drug development in psoriatic arthritis: a trialtrove-based landscape analysis (1999-2025) - PubMed
6 hours ago
- #clinical trials
- #psoriatic arthritis
- #drug development
- Psoriatic arthritis (PsA) drug development analyzed from 587 interventional trials from 1999 to 2025 using Trialtrove data.
- Trial activity increased after 2012, with 82.5% completion, 22.7% positive outcomes, and terminations mainly due to business decisions.
- The United States and China led in trial participation, with diverse funding from academic institutions (35.3%) and top pharmaceutical companies (32.9%).
- TNF inhibitors were most tested, but newer mechanisms like IL-17/IL-23, JAK1/TYK2, and PDE4 pathways gained substantial attention.
- Challenges include heterogeneous endpoints, incomplete reporting, modest efficacy in some novel classes, and cost considerations with biosimilars and generics.
- Future trials should focus on harmonized outcomes, precision patient selection, long-term safety (especially for JAK inhibitors), and treat-to-target designs.